NCT00520780

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 456 (actual)
• Sponsor: Vifor Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.

Conditions

• Chronic Heart Failure
• Iron Deficiency
• Iron Deficiency Anemia
• Anaemia

Interventions

Type	Name	Description
DRUG	Ferinject ® (Ferric carboxymaltose)	Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit. After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
DRUG	Normal saline (0.9%)	During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.

Timeline

• Start date: 2007-04-01
• Primary completion: 2009-07-01
• Completion: 2009-09-01
• First posted: 2007-08-27
• Last updated: 2021-10-14

Locations

48 sites across 10 countries: Argentina, Germany, Greece, Italy, Norway, Poland, Romania, Russia, Spain, Ukraine